Hudson Institute of Medical Research

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Retrieved on: 
Tuesday, September 26, 2023
Royal Australian College of General Practitioners, MESO, Bell, Bachelor, Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Hudson Institute of Medical Research, Rehabilitation, Audit committee, Economics, US, Hospital, Australian Technical Advisory Group on Immunisation, Vulnerability and Risk Committee, AM, United Kingdom, MSB, National Law University, Jodhpur, Therapy, Medical research, Inflammation, Audit

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee.

Key Points: 
  • NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee.
  • The Board thanked retiring Director and Chair of Audit and Risk Committee Mr Michael Spooner for his many years of dedicated service and contributions, and wished him well in his future endeavours.
  • Commenting on her appointment as Chair of the Audit and Risk Committee, Ms Bell said, “My major focus will be to oversee and support management’s ongoing implementation of the Company’s cost containment and cash preservation initiatives.
  • In 2023 Ms Bell was appointed a Member of the Order of Australia (AM) for her significant service to governance in the medical research, healthcare and not-for-profit sectors.

Proactive news headlines including Kinetiko Energy, Noxopharm, Australian Strategic Materials and Aurumin Ltd

Retrieved on: 
Friday, December 16, 2022
Lithium, Medical research, NHMRC, SPP, ABS, MEK, Research, PNX, Hudson Institute, DOE, Proactivity, National Health, OTCQB, LPI, White, ATM, ASX, IBG, National Health and Medical Research Council, SAG, Exercise, CXO, Medical Research Council, NOX, IMU, OTC, MGV, Gold, Hudson Institute of Medical Research, PTL, Fiery Creek, Security (finance), Mining, Renewable energy, Uranium

Click here

Key Points: 
  • Click here
    Alto Metals Ltd (ASX:AME) has raised $2.1 million through an oversubscribed share purchase plan (SPP) and placement.
  • With six offices on three continents, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives to engage intelligently with investors.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected].

BiomeBank Continues Growth Trajectory With Over $10M Capital Raise

Retrieved on: 
Friday, December 9, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biotechnology, State, Human Development Innovation Fund, RMIT, Conditional sentence, The Hospital Research Foundation, Drug discovery, Ulcerative colitis, Research, Bacteria, Patient, Austin Hospital, Melbourne, Collection, GMP, Ecology, Disease, Inflammatory bowel disease, Hudson Institute of Medical Research, Microbiology, Hudson Institute, RMIT University, The Queen Elizabeth Hospital, Adelaide, Clinical trial, Capital, Venture capital, Machine learning, Queen Elizabeth Hospital, Medical research, MIRO, Pharmaceutical industry, Medical device, Antibiotics

BiomeBank today announced the successful capital raise of $10 million following the biotechnology companys world first regulatory approval of its donor derived microbiome drug product.

Key Points: 
  • BiomeBank today announced the successful capital raise of $10 million following the biotechnology companys world first regulatory approval of its donor derived microbiome drug product.
  • This includes BB265, its cultured therapy for ulcerative colitis to allow BiomeBank to conduct its first human clinical trial.
  • Investors that participated in the capital raise include Ellerston Capital and the South Australian Venture Capital Fund, managed by Artesian Venture Partners.
  • The Hospital Research Foundation, who provided founding seed capital and additional support to the company since 2018 committed further capital to this investment round.

Jane Bell Joins Mesoblast Board

Retrieved on: 
Thursday, August 18, 2022
FDA, Royal Australian College of General Practitioners, Risk, United Kingdom, Inflammation, Industry, Death, GLOBE, Forward-looking statement, Technology, Private Securities Litigation Reform Act, Australian Securities Exchange, SEC, Hospital, Board, MSB, Marketing, Hudson Institute of Medical Research, Patient, Therapy, Company, Twitter, Heart, Chief, Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Board of directors, Mesoblast, BLA, LinkedIn, Rehabilitation, MESO, Immune system, Medical research, Pharmaceutical industry, Management

NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors.

Key Points: 
  • NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors.
  • Commenting on her appointment Ms Bell said I look forward to joining the Mesoblast Board at such an exciting stage in the companys transition to a commercial organization, with its deep cell therapy product pipeline.
  • In other board changes, Shawn Tomasello will retire after four years on the Board.
  • Mesoblast Chairman Joseph Swedish welcomed Ms Bell to the Board and thanked Ms Tomasello for her contributions.

Proactive news headlines including White Rock Minerals, Arovella Therapeutics, Critical Resources and Alice Queen

Retrieved on: 
Wednesday, June 22, 2022
Lithium, Elixir, MVL, Well, Ethereum, Hudson Institute of Medical Research, CRR, MRE, PSC, Gold, Antonio, CBM, Ludwig Quidde, OTCQX, OTCQB, Yilgarn Craton, Copper, Tower, GLOBE, Therapy, The Side, ASX, REE, Insomnia, AAU, Mineral resource estimation, AOI, Hyperion, Proactivity, Ironbark, Silver, Anomaly, SPP, White Rock, WRM, ORN, Zinc, EXR, Non-fungible token, MEK, KTA, JSE, AVL, BRK, NOX, Program, Medical research, LSE, CCZ, Mining, Rare-earth element, Oil, The Onedin Line

Click here

Key Points: 
  • Click here
    Arovella Therapeutics Ltd (ASX:ALA) welcomes STADA Australias commercial launch of ZolpiMist (zolpidem tartrate), a product indicated for the short-term treatment of insomnia in adults.
  • Click here
    Meeka Gold Ltd (ASX:MEK) has hit upon pervasive high-value, high-grade rare earths in assays from recent drilling at Circle Valley.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Proactive news headlines including Westar Resources, KGL Resources, Noxopharm and Eclipse Metals

Retrieved on: 
Tuesday, June 14, 2022
Eclipse, Cream, Well, Hydrogen, Copper, OTCQB, Satellite imagery, GTR, La Paz, Therapy, RAD, DIB, Medical research, Hudson Institute of Medical Research, RC, Gold, KMC, The Side, Ironbark, Blue Vein, Controlled Unclassified Information, KZIA, OZM, Brain, IGU, EPM, CPV, CUI, Defense industrial base, TMR, ASX, NETS, CPH, PAB, Patent, RGP, GLH, Contract, Depository Trust Company, RNA, Green Mountain, Isotopia Festival, Acceleration, TSX, DUN, LCT, DTC, Proactivity, UL, News, Neutrophil extracellular traps, MXR, Growth, GLOBE, NASDAQ, FHE, Certification, MEK, Formerly Used Defense Sites, Uranium, Mining, Medical imaging

Click here

Key Points: 
  • Click here
    Eclipse Metals Ltd (ASX:EPM) has welcomed some pleasing results following recent satellite imagery analysis from the multi-commodity Ivittuut Project in south-western Greenland.
  • Click here
    Medallion Metals Ltd (ASX:MM8) has revealed a significantly expanded resource at the Kundip Mining Centre (KMC), part of the 100% owned flagship Ravensthorpe Gold Project (RGP) in Western Australia.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Microbiome Medicine Accelerated by New Partnership Between BiomeBank and Hudson Institute

Retrieved on: 
Wednesday, January 26, 2022
Biotechnology, General Health, Health, Clinical Trials, Reproductive health, Medical research, IBD, Hormone, Series, Bacteria, Research, Patient, Colon, National Centre for Disease Control, Child, Microbiology, Inflammation, Student, Ecology, Biomedical Research, Infant, Pregnancy, Drug discovery, Hudson Institute, Microbiota, Machine learning, Hudson Institute of Medical Research, Health, Disease, CEO, Partnership, Pharmaceutical industry, Medical device, Antibiotics, Cancer, BiomeBank, Hudson Institute, BIOMEBANK, HUDSON INSTITUTE

BiomeBank, which has recently launched its Series-A funding round, has signed a four-year collaborative agreement with Hudson Institute to translate current and future microbiome research into microbial therapies.

Key Points: 
  • BiomeBank, which has recently launched its Series-A funding round, has signed a four-year collaborative agreement with Hudson Institute to translate current and future microbiome research into microbial therapies.
  • Hudson Institute Director and CEO, Professor Elizabeth Hartland added that: The partnership between Hudson Institute and BiomeBank is a critical first step in translating our microbiome discoveries and developing a new generation of treatments for patients.
  • Leading microbiome researcher from Hudson Institute, Dr Samuel Forster said: The partnership will place Australia at the forefront of microbial research and drug discovery.
  • Hudson Institute is home to more than 450 world-class scientists, clinicians and students pioneering outstanding discovery science and translational research.

Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

Retrieved on: 
Wednesday, December 1, 2021
Research, Other Health, General Health, Professional Services, Pharmaceutical, Oncology, Infectious Diseases, Clinical Trials, Science, Biotechnology, Finance, Health, Other Science, Patient, Hudson Institute of Medical Research, Safety, Septic shock, Technology, Inflammation, Chills, TLR7, ASX, Metabotropic glutamate receptor 7, Cancer, Health, Autoimmunity, NOX, Headache, Therapy, Cytokine release syndrome, Degenerative disease, Research, RNA, TBK1, NYR, RNA transfection, Associate, Medical research, Drug development, Fatigue, Vaccine, Pharmaceutical industry, Noxopharm, Hudson Institute of Medical Research, NOXOPHARM, HUDSON INSTITUTE OF MEDICAL RESEARCH

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology developed by Hudson Institute of Medical Research .

Key Points: 
  • Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology developed by Hudson Institute of Medical Research .
  • According to Noxopharm CEO and Managing Director, Graham Kelly , Pharmorage already had a strong business relationship with Hudson with a major initiative in anti-inflammatory drug development.
  • A global bioscience medical research leader, Hudson Institutes sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives.
  • It strives to improve human health through groundbreaking, collaborative, medical research discoveries and the translation of these to real world impact.

Proactive news headlines including West Wits Mining, Eclipse Metals, Bellevue Gold and Calima Energy

Retrieved on: 
Wednesday, November 17, 2021
Eclipse, Well, ADN, EPM, YRL, PXS, Rafael, Laboratory, Magnesium chloride, Ivittuut, Hudson Institute of Medical Research, OTC, Helium, Gold, Barwidgee, Victoria, Volunteering, Ranger, Technology, SVM, Research, AIM, GLOBE, Flushing Meadows–Corona Park, ASX, BBB, CCZ, AOI, LSE, London Stock Exchange, Kambalda, Western Australia, Medical research, Proactivity, FAK, SOP, ATX, Throsby, RNA, Water, BNL, Anomaly, London, Oil, Rare-earth element, Security (finance), Lithium

Click here

Key Points: 
  • Click here
    Bellevue Gold Ltd (ASX:BGL) has enhanced its project development team by appointing highly experienced resources executives Darren Stralow and Bill Stirling as chief executive officer and general manager respectively.
  • Click here
    Calima Energy Ltd (ASX:CE1) shares are trading higher after commencing flow back and production from three wells at its Throsby asset in Alberta, Canada.
  • Click here
    Andromeda Metals Ltd (ASX:ADN) has established a Technical Advisory Committee to steer its research and development programs and provide advice on business prospects.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006
    For more information on how Proactive can help you make a difference, email us at [email protected]

Bacainn Therapeutics’ Ashley Mansell to Present on BT032, a Novel First-in-Class NLRP1 and NLRP3 Inhibitor, at the 3rd Inflammasome Therapeutics Digital Summit

Retrieved on: 
Friday, November 12, 2021
Health, Biotechnology, NLRP3, Therapy, Ulcerative colitis, NLRP1, Doctor of Philosophy, Inflammation, Inflammasome, Research and development, Hudson Institute of Medical Research, Principal investigator, Medical research, Pharmaceutical industry

Dr. Mansells presentation will focus on the discovery and characterization of BT032, a novel dual NLRP1 and NLRP3 inhibitor, and its potential application for the treatment of pulmonary inflammation.

Key Points: 
  • Dr. Mansells presentation will focus on the discovery and characterization of BT032, a novel dual NLRP1 and NLRP3 inhibitor, and its potential application for the treatment of pulmonary inflammation.
  • Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation.
  • The company was founded on novel and extensive insights into neutrophil and inflammasome biology which allow for potentially new and bold approaches to treating inflammatory diseases.
  • Bacainns lead asset, BT051, is currently in clinical development for the treatment of moderate to severe ulcerative colitis.